Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 160 50 versus INDERIDE 40 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 160 50 versus INDERIDE 40 25.
INDERIDE LA 160/50 vs INDERIDE-40/25
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Propranolol: Non-selective beta-adrenergic receptor antagonist (blocks β1 and β2 receptors). Hydrochlorothiazide: Thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule, reducing intravascular volume by increasing sodium and water excretion.
Inderide-40/25 is a combination of propranolol (non-cardioselective beta-blocker) and hydrochlorothiazide (thiazide diuretic). Propranolol reduces heart rate, myocardial contractility, and renin secretion via beta-adrenergic receptor blockade. Hydrochlorothiazide inhibits Na+/Cl- cotransporter in distal convoluted tubule, increasing excretion of Na+, Cl-, and water; also reduces peripheral vascular resistance.
HypertensionAngina pectoris (propranolol)Migraine prophylaxis (propranolol)Essential tremor (propranolol)Edematous states (hydrochlorothiazide)
HypertensionAdjunctive therapy in hypertension not adequately controlled with monotherapy
One capsule orally once daily. Each capsule contains propranolol hydrochloride 160 mg and hydrochlorothiazide 50 mg. Dosage should be individualized; typical maintenance dose is 1 capsule per day.
One tablet (40 mg propranolol HCl/25 mg hydrochlorothiazide) orally twice daily; may increase to maximum of 160 mg propranolol/100 mg hydrochlorothiazide per day in divided doses.
None Documented
None Documented
Propranolol: 3-6 hours (parent drug), 8-12 hours (4-hydroxypropranolol active metabolite) with prolonged half-life in hepatic impairment; Hydrochlorothiazide: 6-15 hours, extended in renal impairment (creatinine clearance <30 mL/min).
Propranolol: 3-6 hours (terminal); clinical context: dosing 2-3 times daily due to short half-life; may accumulate in hepatic impairment. Hydrochlorothiazide: 6-15 hours (terminal); clinical context: longer in renal impairment.
Propranolol: Hepatic via CYP2D6 and glucuronidation; active metabolite 4-hydroxypropranolol. Hydrochlorothiazide: Not extensively metabolized, excreted unchanged in urine.
Propranolol: extensively metabolized by CYP2D6 and CYP1A2 to active metabolite 4-hydroxypropranolol; also undergoes glucuronidation. Hydrochlorothiazide: not metabolized, excreted unchanged by kidneys.
Propranolol: primarily hepatic metabolism to inactive metabolites, <1% excreted unchanged in urine; Hydrochlorothiazide: 50-70% excreted unchanged in urine, remainder as metabolites via renal and biliary routes.
Propranolol: extensively metabolized in liver via CYP2D6 and glucuronidation; <1% excreted unchanged in urine. Hydrochlorothiazide: ~70% excreted unchanged in urine via tubular secretion.
Propranolol: 90-95% bound to albumin; Hydrochlorothiazide: 40-68% bound to albumin.
Propranolol: 90% bound primarily to albumin; hydrochlorothiazide: 40-68% bound to plasma proteins.
Propranolol: 3-5 L/kg, indicating extensive tissue penetration; Hydrochlorothiazide: 0.83-1.14 L/kg, consistent with distribution into extracellular fluid.
Propranolol: 3.0-4.7 L/kg (extensive tissue distribution; crosses blood-brain barrier). Hydrochlorothiazide: 0.8-1.2 L/kg (confined to extracellular fluid).
Propranolol: 25-30% due to extensive first-pass hepatic metabolism; Hydrochlorothiazide: 65-75% after oral administration.
Propranolol: absolute oral bioavailability ~30% due to extensive first-pass metabolism; range 20-70% interindividual. Hydrochlorothiazide: oral bioavailability ~60-80% (50-80% in some sources).
For GFR <30 mL/min: contraindicated due to thiazide component. For GFR 30-60 mL/min: reduce dose or increase interval based on clinical response; monitor electrolytes and renal function.
For GFR 30-50 mL/min: reduce dose by 50% or use alternative. For GFR <30 mL/min: contraindicated due to hydrochlorothiazide component.
In Child-Pugh A: reduce propranolol dose by 50%. Child-Pugh B or C: avoid use or use with extreme caution; propranolol undergoes extensive hepatic metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: reduce propranolol dose by 50%; Child-Pugh C: avoid use.
Safety and efficacy not established; not recommended for use in pediatric patients.
Not recommended for use in children; safety and efficacy not established.
Initiate at lower dose (e.g., one-half capsule) due to increased sensitivity and age-related renal/hepatic decline; titrate slowly. Monitor orthostatic hypotension, bradycardia, and electrolyte disturbances.
Initiate at lowest dose (one tablet once daily) and titrate slowly; monitor for hypotension, bradycardia, and electrolyte disturbances.
No black box warning is listed for INDERIDE LA 160/50 in standard FDA labeling. Propranolol may exacerbate angina and precipitate myocardial infarction with abrupt discontinuation; taper dose gradually.
Exacerbation of angina and myocardial infarction upon abrupt discontinuation: Beta-blocker withdrawal may precipitate angina and, in patients with coronary artery disease, myocardial infarction. Taper dose gradually over 1-2 weeks.
Heart failure, bronchospasm (asthma/COPD), bradycardia, hypotension, peripheral vascular disease, thyrotoxicosis (may mask signs), myocardial ischemia (abrupt withdrawal), diabetes (mask hypoglycemia), electrolyte imbalance (especially hypokalemia from thiazide), hyperuricemia, systemic lupus erythematosus exacerbation.
Abrupt discontinuation, bronchospasm in asthmatics, masking of hypoglycemia in diabetics, bradycardia/heart block, worsening heart failure, hypotension, electrolyte disturbances (hypokalemia, hyponatremia), hyperuricemia, acute angle-closure glaucoma, exacerbation of peripheral vascular disease.
Cardiogenic shock, sinus bradycardia, second- or third-degree AV block, sick sinus syndrome (without pacemaker), overt heart failure, bronchial asthma, hypersensitivity to beta-blockers or thiazides, anuria, severe renal impairment (creatinine clearance <30 mL/min).
Cardiogenic shock, sinus bradycardia, second- or third-degree AV block, severe asthma or COPD, hypersensitivity to sulfonamide-derived drugs (hydrochlorothiazide), anuria, concomitant treatment with MAOIs (except MAO-B inhibitors).
Data Pending Review
Data Pending Review
Avoid high-potassium foods (e.g., bananas, oranges, spinach, salt substitutes) in excess, as hydrochlorothiazide affects potassium balance. Limit alcohol consumption. Maintain a low-sodium diet to reduce fluid retention and enhance antihypertensive effect. Avoid grapefruit products as they may alter drug metabolism.
Avoid excessive salt intake; potassium-rich foods (bananas, oranges) may be beneficial but monitor potassium levels if on other potassium-altering drugs. Grapefruit juice may increase propranolol levels; avoid concurrent use.
Propranolol (component of Inderide LA 160/50) crosses the placenta and is associated with intrauterine growth restriction, neonatal hypoglycemia, bradycardia, and respiratory depression, especially with third-trimester exposure. First-trimester use may increase risk of spontaneous abortion. Risk cannot be excluded; use only if benefit outweighs risk.
First trimester: Avoid use due to possible association with congenital malformations (e.g., cardiovascular defects) based on limited studies. Second and third trimesters: Associated with fetal bradycardia, intrauterine growth restriction, oligohydramnios, and neonatal hypoglycemia. Risk of hypoperfusion and hypoxia in fetus if maternal hypotension occurs.
Both propranolol and hydrochlorothiazide are excreted into breast milk. Propranolol M/P ratio: 0.5-1.5. Hydrochlorothiazide may suppress lactation. American Academy of Pediatrics considers propranolol compatible but caution with hydrochlorothiazide. Monitor infant for bradycardia, hypotension, and electrolyte disturbances.
Both propranolol and hydrochlorothiazide are excreted into breast milk. Propranolol milk-to-plasma ratio approximately 1.0. Hydrochlorothiazide M/P ratio 0.1–0.8. Use caution: potential for adverse effects in nursing infant (bradycardia, hypotension, electrolyte disturbances).
Pregnancy may increase clearance of propranolol, potentially requiring higher doses to maintain efficacy. Dose adjustment should be guided by clinical response and maternal heart rate. Avoid use of hydrochlorothiazide in pregnancy due to risk of fetal/neonatal adverse effects; consider alternative antihypertensive.
Monitor maternal blood pressure and heart rate: dose may need reduction due to increased plasma volume and clearance changes. Hydrochlorothiazide: risk of volume depletion and electrolyte imbalances; use lowest effective dose. Propranolol: increased hepatic clearance may require dose adjustment; avoid abrupt discontinuation.
Category C
Category C
INDERIDE LA 160/50 combines propranolol HCl (160 mg) and hydrochlorothiazide (50 mg). Monitor heart rate and blood pressure regularly; propranolol can mask hypoglycemia symptoms in diabetics and thyrotoxicosis. Hydrochlorothiazide may cause electrolyte disturbances; check potassium, magnesium, and sodium. Avoid abrupt withdrawal due to risk of angina exacerbation or MI. Use with caution in patients with asthma, COPD, bradycardia, or heart block.
Inderide 40/25 (propranolol 40mg/hydrochlorothiazide 25mg) is a fixed-dose combination for hypertension. Propranolol is a non-selective beta-blocker; avoid in asthma, COPD, and heart block. Hydrochlorothiazide may cause hypokalemia; monitor electrolytes. Use with caution in diabetes (masks hypoglycemia) and peripheral vascular disease. Taper beta-blockers slowly to avoid rebound hypertension.
Take this medication exactly as prescribed, usually once daily in the morning.Do not stop taking this medication suddenly without consulting your doctor, as this may worsen chest pain or increase risk of heart attack.This drug may cause dizziness or lightheadedness; avoid driving if affected and rise slowly from sitting or lying position.Monitor your blood pressure regularly and keep a log to share with your healthcare provider.If you have diabetes, check your blood sugar more often; propranolol can hide signs of low blood sugar like rapid heartbeat.Avoid alcohol as it may increase side effects like dizziness or drowsiness.Report any unusual weight gain, swelling, excessive thirst, dry mouth, or muscle cramps to your doctor.Do not take other medications for blood pressure or heart conditions without doctor approval.Limit caffeine intake as it may increase heart rate and counteract the effects.
Take exactly as prescribed; do not skip doses or double up.May cause dizziness or fatigue; avoid driving until effects known.Avoid sudden discontinuation; can cause rapid heart rate or hypertension.Limit alcohol and NSAIDs; they may increase blood pressure or reduce effect.Report shortness of breath, unusual weight gain, or swelling of extremities.Monitor blood pressure regularly and keep appointments for lab tests (potassium, renal function).May increase sensitivity to cold; dress warmly.